| [1] |
Rosenberg IH. Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19-21, 1988[J]. Am J Clin Nutr, 1989, 50(5 Suppl): 1121-235.
|
| [2] |
von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact[J]. J Cachexia Sarcopenia Muscle, 2010, 1(2): 129-133.
|
| [3] |
Zhuang CL, Huang DD, Pang WY, et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort[J]. Medicine (Baltimore), 2016, 95(13): e3164.
|
| [4] |
Wang SL, Zhuang CL, Huang DD, et al. Sarcopenia adversely impacts postoperative clinical outcomes following gastrectomy in patients with gastric cancer: A prospective study[J]. Ann Surg Oncol, 2016, 23(2): 556-564.
|
| [5] |
Wong R, Wong H, Zhang N, et al. The relationship between sarcopenia and fragility fracture-a systematic review[J]. Osteoporos Int, 2019, 30(3): 541-553.
|
| [6] |
Aprile G, Basile D, Giaretta R, et al. The clinical value of nutritional care before and during active cancer treatment[J]. Nutrients, 2021, 13(4): 1196.
|
| [7] |
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People[J]. Age Ageing, 2010, 39(4): 412-423.
|
| [8] |
Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia[J]. J Am Med Dir Assoc, 2014, 15(2): 95-101.
|
| [9] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [10] |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
|
| [11] |
Goodlad GA, Tee MK, Clark CM. Leucine oxidation and protein degradation in the extensor digitorum longus and soleus of the tumor-bearing host[J]. Biochem Med, 1981, 26(2): 143-147.
|
| [12] |
Abrigo J, Simon F, Cabrera D, et al. Mitochondrial dysfunction in skeletal muscle pathologies[J]. Curr Protein Pept Sci, 2019, 20(6): 536-546.
|
| [13] |
Hyatt H, Deminice R, Yoshihara T, et al. Mitochondrial dysfunction induces muscle atrophy during prolonged inactivity: A review of the causes and effects[J]. Arch Biochem Biophys, 2019, 662: 49-60.
|
| [14] |
Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease[J]. Nat Commun, 2021, 12(1): 330.
|
| [15] |
Bodine SC. Edward F. Adolph Distinguished Lecture. Skeletal muscle atrophy: multiple pathways leading to a common outcome[J]. J Appl Physiol (1985), 2020, 129(2): 272-282.
|
| [16] |
Bano G, Trevisan C, Carraro S, et al. Inflammation and sarcopenia: A systematic review and Meta-analysis[J]. Maturitas, 2017, 96: 10-15.
|
| [17] |
Miki Y, Morioka T, Shioi A, et al. Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation[J]. Biochem Biophys Res Commun, 2019, 516(3): 951-956.
|
| [18] |
Patel HJ, Patel BM. TNF-α and cancer cachexia: molecular insights and clinical implications[J]. Life Sci, 2017, 170: 56-63.
|
| [19] |
de Alvaro C, Teruel T, Hernandez R, et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner[J]. J Biol Chem, 2004, 279(17): 17070-17078.
|
| [20] |
吴国豪. 癌性恶病质发生机制及防治对策[J]. 中国实用外科杂志, 2015, 35(1): 36-39.
|
| [21] |
Biswas AK, Acharyya S. Understanding cachexia in the context of metastatic progression[J]. Nat Rev Cancer, 2020, 20(5): 274-284.
|
| [22] |
White JP, Puppa MJ, Sato S, et al. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse[J]. Skelet Muscle, 2012, 2: 14.
|
| [23] |
Kasembeli MM, Bharadwaj U, Robinson P, et al. Contribution of STAT3 to inflammatory and fibrotic diseases and prospects for its targeting for treatment[J]. Int J Mol Sci, 2018, 19(8): 2299.
|
| [24] |
Ma DW, Cho Y, Jeon MJ, et al. Relationship between sarcopenia and prognosis in patient with concurrent chemo-radiation therapy for esophageal cancer[J]. Front Oncol, 2019, 9: 366.
|
| [25] |
Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy[J]. Ann Palliat Med, 2019, 8(1): 86-101.
|
| [26] |
Oflazoglu U, Alacacioglu A, Varol U, et al. Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study[J]. Support Care Cancer, 2020, 28(6): 2899-2910.
|
| [27] |
Sugawara K, Yamashita H, Urabe M, et al. Poor nutritional status and sarcopenia influences survival outcomes in gastric carcinoma patients undergoing radical surgery[J]. Eur J Surg Oncol, 2020, 46(10 Pt A): 1963-1970.
|
| [28] |
Makal GB, Aslan A. Is sarcopenia really a risk factor in the development of postoperative complications?[J]. Surg Oncol, 2021, 37: 101527.
|
| [29] |
O’Brien S, Twomey M, Moloney F, et al. Sarcopenia and post-operative morbidity and mortality in patients with gastric cancer[J]. J Gastric Cancer, 2018, 18(3): 242-252.
|
| [30] |
Tan BH, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer[J]. Eur J Surg Oncol, 2015, 41(3): 333-338.
|
| [31] |
Zhou CJ, Zhang FM, Zhang FY, et al. Sarcopenia: A new predictor of postoperative complications for elderly gastric cancer patients who underwent radical gastrectomy[J]. J Surg Res, 2017, 211: 137-146.
|
| [32] |
National Cancer Institute. Surveillance, epidemiology, and end results program[DB/OL]. Bethesda (MD): National Cancer Institute[2022-04-11].
URL
|
| [33] |
Zhang S, Tan S, Jiang Y, et al. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study[J]. Clin Nutr, 2019, 38(6): 2881-2888.
|
| [34] |
Kouzu K, Tsujimoto H, Sugasawa H, et al. Impact of postoperative reduced skeletal muscle on prognosis after recurrence in gastric cancer[J]. Mol Clin Oncol, 2021, 14(1): 3.
|
| [35] |
Kuwada K, Kuroda S, Kikuchi S, et al. Sarcopenia and comorbidity in gastric cancer surgery as a useful combined factor to predict eventual death from other causes[J]. Ann Surg Oncol, 2018, 25(5): 1160-1166.
|
| [36] |
Mirkin KA, Luke FE, Gangi A, et al. Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: A multi-institutional analysis[J]. J Gastrointest Oncol, 2017, 8(3): 589-595.
|
| [37] |
Cruz-Jentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
|
| [38] |
Shea MK, Fielding RA, Dawson-Hughes B. The effect of vitamin D supplementation on lower-extremity power and function in older adults: A randomized controlled trial[J]. Am J Clin Nutr, 2019, 109(2): 369-379.
|
| [39] |
Kemmler W, Kohl M, Fröhlich M, et al. Effects of high-intensity resistance training on osteopenia and sarcopenia parameters in older men with osteosarcopenia-one-year results of the randomized controlled Franconian Osteopenia and Sarcopenia Trial (FrOST)[J]. J Bone Miner Res, 2020, 35(9): 1634-1644.
|
| [40] |
Cao A, Ferrucci LM, Caan BJ, et al. Effect of exercise on sarcopenia among cancer survivors: A systematic review[J]. Cancers (Basel), 2022, 14(3): 786.
|
| [41] |
Conte E, Camerino GM, Mele A, et al. Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia[J]. J Cachexia Sarcopenia Muscle, 2017, 8(3): 386-404.
|
| [42] |
La Colla A, Pronsato L, Milanesi L, et al. 17β-estradiol and testosterone in sarcopenia: role of satellite cells[J]. Ageing Res Rev, 2015, 24(Pt B): 166-177.
|